




Supplementary Materials for 
 
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune 
responses against HIV-1 
Till Schoofs, Florian Klein, Malte Braunschweig, Edward F. Kreider, Anna Feldmann, 
Lilian Nogueira, Thiago Oliveira, Julio C. C. Lorenzi, Erica H. Parrish, Gerald H. Learn, 
Anthony P. West Jr, Pamela J. Bjorkman, Sarah J. Schlesinger, Michael S. Seaman, Julie 
Czartoski, M. Juliana McElrath, Nico Pfeifer, Beatrice H. Hahn, Marina Caskey, Michel C. 
Nussenzweig* 
 
*Corresponding author. Email: nussen@rockefeller.edu 
 
Published 5 May 2016 on First Release 
DOI: 10.1126/science.aaf0972 
 
This PDF file includes: 
 
Materials and Methods 
Figs. S1 to S10 






Materials and Methods 
Study participants 
Study participants that received 3BNC117 were all part of the 3BNC117 Phase-I 
open-label clinical trial NCT02018510 (16). The protocol was approved by the Federal 
Drug Administration in the USA, the Paul Ehrlich Institute in Germany and the 
Institutional Review Boards at the Rockefeller University, the University of Cologne, 
Weill Cornell Medical College and the Brigham and Women’s Hospital Boston. The 
control cohort of untreated viremic HIV-1-infected subjects were study participants in 
Seattle Vaccine Unit Observational Protocols 4712 and 4325 (P.I. MJ McElrath). 
Subjects were recruited from the Seattle, WA community through advertisements and 
referrals from care providers. All participants provided written informed consent before 
participation in the studies and the studies were conducted in accordance with Good 
Clinical Practice.  
 
ELISA of 3BNC117 serum levels 
3BNC117 serum concentrations were determined using a validated sandwich ELISA 
as previously described (16). Lower limit of accuracy of the ELISA assay was 
determined to be 2 µg/ml. Patients for whom background > 0.50 µg/ml at Day 0 baseline 
was detected (Subjects 2A4, 2B3, 2C2, 2C4, 2C1 and 2E2) were excluded from the 
illustration of 3BNC117 serum levels shown in Figure 1A. 
 
Virus cultures 
Virus from study participants was obtained by co-culture of patient peripheral blood 
mononuclear cells (PBMCs) with healthy donor PBMCs as previously described (42). 
Healthy donor PBMCs were obtained from patients by leukapheresis under study 
protocol MNU-0628 at Rockefeller University. All donors provided written informed 
consent before participation. Healthy donor PBMCs were pre-stimulated at a density of 5 
x 106 cells ml-1 in IMDM containing 10% FBS, 1% Penicillin-Streptomycin and PHA at 
1 µg ml-1 for 2-3 days at 37°C and 5% CO2. 6 x 106 of the stimulated donor PBMCs were 
then transferred to IMDM containing 10% FBS, 1% Penicillin-Streptomycin, 10 IU IL-2 
ml-1 and 5 µg ml-1 polybrene and co-cultured with 5-10 x 106 patient PBMCs at 37°C and 
5% CO2. Media was replaced weekly and the presence of p24 in culture supernatant was 
quantified by Lenti-X p24 Rapid Titer Kit (Clontech). Cultures exceeding 1 ng/ml of p24 
per ml of supernatant were frozen and stored at -80°C. Determination of tissue culture 
infectious dose 50 (TCID50) and subsequent testing for sensitivity of autologous viruses 
to different broadly neutralizing antibodies and autologous serum IgG was carried out 
using a TZM.bl neutralization assay according to established protocols (43, 44). All 
neutralization assays were run in duplicates. 
 
Antibody neutralization testing by TZM.bl 
To determine heterologous neutralizing activity, patient sera or purified IgG were 
tested against a defined panel of pseudoviruses in TZM.bl assay as previously described 
(21, 43). IgG was purified from patient plasma using Protein G Sepharose 4 Fast Flow 
according to manufacturer’s instructions. All neutralization assays were conducted in a 





(Michael S. Seaman, Beth Israel Deaconess Medical Center). Samples from 3BNC117-
treated patients and controls were tested in intermingled batches at a variety of different 
time points. All neutralization assays were run in duplicates. 
 
Antibody-strain coverage curves 
Total IgG coverage curves ((1/AUC) vs. percent of strains neutralized) were 
generated using Antibody database v2.0 (45). 
 
Area under the curve calculation of antibody neutralization 
The area under the curve (AUC) was calculated using the neutralization (y-axis) at a 
particular measured concentration level (x-axis) using the R package flux (version 0.2.1.). 
In order to have equal distance between concentration levels, concentration levels were 
logarithmized using the natural logarithm. Since mean neutralization activity of both 
treated and the control group towards murine leukemia virus (MuLV) was around 7%, a 
neutralization of 10% was considered background noise. In addition, we tested at which 
concentration level the standard deviation (sd) of the assay exceeded variation due to 
neutralization. For neutralization by total IgG, only concentrations greater than 6.173 
ug/ml were taken into consideration since the measurement variation exceeded changes 
in antibody neutralization below this level (i.e. concentration levels used to calculate 
AUCs were 500 µg/ml, 166.667 µg/ml, 55.556 µg/ml, 18.519 µg/ml and 6.173 µg/ml).  
 
Statistical tests of heterologous neutralization AUC data 
In Figure 2A, mean AUC difference values of off/on-ART patients were compared 
to mean AUC differences of control patients with an unpaired Wilcoxon test (rank-sum 
test).  
 
For Figure 2B pairwise testing was performed if AUC difference values are different 
for different groups (i.e., control group, treated while off-ART, and treated while on-
ART). The model was built using generalized estimating equations for a model with 
intercept and group as the only covariate (38). Equicorrelated measurements within a 
cluster (patient) were assumed and normal distribution was used. p-values were estimated 
for the null-hypothesis that the weight parameter of the group covariate is zero. 
GEEQBOX version 1.0 was used for calculations (38). 
 
For Figure 2D, AUC difference values of controls were compared to the AUC 
difference values of the off-ART (panel 2) or on-ART (panel 3) 3BNC117-treated 
patients using an unpaired Wilcoxon test (rank-sum test). This was performed for each 
virus separately. A star is shown if the p-value was significant after Bonferroni correction 
((p-value <= (0.05 / # tests)) = (p-value <= 0.003846154)). 
 
To exclude that leftover amounts of 3BNC117 could explain the neutralization 
increase observed in 3BNC117-treated individuals, the Spearman rank correlation of 
neutralization changes in each patient with the neutralization profile of 3BNC117 was 
calculated (Fig. S5, Table S8). Rank correlation was calculated using both IC50 and AUC 
values. p-values were corrected for multiple testing by Bonferroni-correction (p-value <= 






Analysis of confounding variables 
To determine whether the observed difference in AUC improvement between 
3BNC117-treated individuals and viremic controls was confounded by variables such as 
age, time of infection and starting AUC, a systematic confounder analysis was 
performed. For each variable and each virus (Table S7), we tested whether the variable is 
predictive for the observed AUC difference. To do so, a linear regression model 
(intercept only/null model) was compared to an extended model that considered the 
variable in question. A likelihood ratio test asking whether the extended model is superior 
to the linear model was performed (Table S7). To compute the bayes factors for the 
likelihood ratio test, the R package BayesFactor (version 0.9.2) was used. A total of 8 
features was tested across each of 13 viruses (total = 104 tests).  
 
Single genome sequencing (SGS) of HIV-1 env genes  
HIV-1-RNA was extracted from patient plasma using the Qiagen MinElute Virus 
Spin Kit according to manufacturer’s instructions. Extracted RNA was subjected to env-
specific cDNA Synthesis using SuperScript III Reverse Transcriptase and primer 
envB3out 5’– TTGCTACTTGTGATTGCTCCATGT 3’. Remaining RNA was digested 
using RNAseH for 20 minutes at 37 °C before diluted cDNA was subjected to two-
rounds of nested PCR with gp160-specific primers. First round PCR was performed in a 
20 ul volume containing 1x High Fidelity buffer, 2 mM MgSO4, 0.2 mM dNTPs and 0.5 
units of High Fidelity Platinum Taq using 0.2 uM each of primers envB5out 
5’TAGAGCCCTGGAAGCATCCAGGAAG 3’ and envB3out 5’ 
TTGCTACTTGTGATTGCTCCATGT 3’. PCR conditions were 94 °C, 2min; (94 °C, 
15s; 55 °C 30s; 68 °C, 4min) x 35; 68 °C, 15min. Second round PCR was performed 
using 1 ul of PCR 1 and 0.2 uM of primers of envB5in 5’ 
TTAGGCATCTCCTATGGCAGGAAGAAG 3’ and envB3in 5’– 
GTCTCGAGATACTGCTCCCACCC 3’. PCR conditions were the same as PCR-1 
except for 45 cycles and an increased annealing temperature of 58 °C. PCR2 products 
were checked using 1% 96-well E-Gels (Invitrogen). Bands from PCRs with 
amplification efficiencies lower than 30% were subjected to library preparation using the 
Illumina Nextera DNA Sample Prepration Kit (Illumina) as described (46). Briefly, 10 ng 
of DNA per band were subjected to tagmentation, ligated to barcoded sequencing 
adapters using the Illumina Nextera Index Kit and then purified using AmPure Beads XP 
(Agencourt). 96 different purified samples were pooled into one library and then 
subjected to paired-end MiSeq Sequencing using the Illumina Miseq Nano 300 cycle kits 
at a concentration of 12 pM. 
 
Bioinformatic processing of MiSeq env-sequences 
Sequence adapters were removed using Cutadapt v1.8.3. Read assembly for each 
virus was performed in three steps. First, de novo assembly was performed using Spades 
v3.6.1 to yield long contig files. Contigs longer than 255bp were subsequently aligned to 
an HIV envelope reference sequence and a consensus sequence was generated using 
Geneious 8. Finally, reads were re-aligned to the consensus sequence to close gaps and a 
final consensus was generated. Sequences with double peaks (cutoff consensus identity 






Analysis of viral evolution 
Alignments of env nucleotide sequences were generated using ClustalW (version 
2.11) (47) or via manual alignment using Geneious (version 8.1.6) sequence analysis 
software (48). Regions that could not be unambiguously aligned were removed for 
phylogenetic analysis and diversity calculations. Evolutionary model classes for 
maximum likelihood phylogenetic analyses were selected using jModelTest (49). 
Maximum likelihood phylogenetic trees were generated using PhyML (version 3) (50) 
with joint estimation of model parameter values and phylogenies. Within-patient trees 
were midpoint rooted and colored using the Rainbow Tree webtool through the Los 
Alamos National Laboratory (LANL) HIV Database 
(http://www.hiv.lanl.gov/content/sequence/RAINBOWTREE/rainbowtree.html). 
Pairwise genetic distances were calculated using PhyML (50) in the DIVEIN webtool 
(http://indra.mullins.microbiol.washington.edu/DIVEIN/diver.html) (41) using the Jukes-
Cantor model of nucleotide substitution or the HIVw model of amino acid substitution 
(51). Pairwise genetic diversity was compared among samples using a two-sample U-
statistic test (39, 40) in the DIVEIN webtool (41).  
 
Highlighter plots were generated using the LANL nucleotide and amino acid 
Highlighter tools 
(http://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter_top.html). To 
generate Day 0 consensus sequences, each site was assigned the residue present in the 
highest frequency in Day 0 sequences. Gaps were treated as characters and sites without a 
single, most common residue were assigned ”X.”  
 
Longitudinal modified weblogo plots of 3BNC117 contacts were generated using 
LASSIE (Longitudinal Antigenic Sequences and Sites from Intrahost Evolution) (28). 
Sites under significant selection (cutoff ≥80% new amino acid residue in particular 
position relative to Day 0 consensus) were determined and graphed using LASSIE. 
 
Generation of CMV-env based pseudoviruses 
CMV-env expression cassettes were generated according to an established protocol 
(52). Briefly, the CMV promoter was amplified from pcDNA 3.1D/V5-His-TOPO 
Expression vector using the primers CMVenv 
5’AGTAATCAATTACGGGGTCATTAGTTCAT 3’and CMVenv1A 
5’CATAGGAGATGCCTAAGCCGGTGGAGCTCTGCTTATATAGACCTC 3’. The 
PCR product was purified using the Macherey-Nagel PCR and Gel Purification Kit. 
1 ul of first round PCR product was amplified using primers env1ATOPO  5’ CACC 
GGCTTAGGCATCTCCTATGGCAGGAAGAA  3’ and Rev19 5’ 
ACTTTTTGACCACTTGCCACCCAT 3’ in a 20 ul volume containing 1x High Fidelity 
Buffer, 2 mM MgSO4, 0.2 mM dNTPs, 0.5 units of High Fidelity Platinum and 0.2 uM 
of each primer. Cycling conditions were 94 °C, 2min; (94 °C, 15s; 55 °C 30s; 68 °C, 
4min) x 35; 68 °C, 10min. The presence of env was validated by analysis on a 0.7% 
Agarose gel and the product was purified using the Macherey-Nagel Gel and PCR 
Purification Kit. 10 ng of envelope and 0.5 ng of CMV were then subjected to 





was 50 ul containing 1x High Fidelity Buffer, 0.2 uM MgS04, 0.2 mM dNTPs, 1 U of 
Platinum Taq High Fidelity and 0.4 uM of each primer. PCR was carried out at 94 °C, 
2min; (94 °C, 30s; 60 °C 30s; 68 °C, 4min) x 25; 68 °C, 10min. 500 ng of CMV-env 
were co-transfected with pSG3Δenv in 6-well plates into 293T cells and supernatant was 
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Wk24 (end of observation)
Fig. S1.
 
Dynamics of neutralization potency and breadth in each individual. Graphs show 
relationship between neutralization potency (1/AUC, x-axis) and breadth of neutraliza-
tion (% of strains neutralized, y-axis) on Day 0 (grey) and at end of observation period 
(respective color for each group of study). A. untreated viremic control individuals 
(yellow). B. 3BNC117-treated individuals off-ART (dark blue) and 3BNC117-treated 
individuals on-ART (light blue) 
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Dynamics of neutralization potency and breadth in each individual. Graphs show 
relationship between neutralization potency (1/AUC, x-axis) and breadth of neutraliza-
tion (% of strains neutralized, y-axis) on Day 0 (grey) and at end of observation period 
(respective color for each group of study). A. untreated viremic control individuals 
(yellow). B. 3BNC117-treated individuals off-ART (dark blue) and 3BNC117-treated 
individuals on-ART (light blue) 
Fig. S2. 
Dynamics of neutralization breadth by group of study. Bar plot illustrating the mean 
percentage of viruses neutralized (cutoff AUC ≥ 0.5) on Day0 and at the end of obser-
vation period by group of study. p-values determined using two-tailed Wilcoxon 
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controls
A Age B Years since Diagnosis C
D
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Starting AUC E FCD4+ T-cell count Viral load
Fig. S3. 
Comparison of clinical parameters between groups. Scatter dot plot of clinical parame-
ters by patient group. Colored bars represent mean values of each group. p-values 
(indicated in red when significant) determined by unpaired Wilcoxon rank-sum test. 
Two hypotheses were tested for each parameter yielding a Bonferroni-corrected signifi-
cance threshold of 0.025 with significance level α = 0.05. n.s. = not significant. All 
parameters were tested in a confounder analysis and none of the parameter differences 
































































































































































































































































Heterologous neutralization Day 0 
(mean AUC of 13 strains)
R2 = 0.1106
r = - 0.33
Fig. S4. 
Correlation between starting AUC and AUC increase. A. Scatter plot of Day 0 AUC 
data (x-axis) and AUC difference W24-D0 (y-axis). Each dot shows the AUC data for a 
single virus from a single patient. B. Scatter plot of mean day 0 AUC data (x-axis) and 
mean AUC difference W24-D0 (y-axis). Each dot shows the mean data across all 13 
viral strains for a particular patient. A linear fit model (dashed red line) is added with 















































































































































































































































































































































p = 0.1689 p = 0.2470 p = 0.1926 p = 0.9924
p = 0.5135 p = 0.2250 p = 0.8815 p = 0.0103
p = 0.3425 p = 0.0001 p = 0.0160 p = 0.1926
p = 0.5292 p = 0.0850 p = 0.1013
Fig. S5. 
Neutralization profile comparison of AUC change in 3BNC117-treated individuals 
with neutralization profile of 3BNC117. For each individual the individual’s AUC 
change (Wk24 - Day 0 AUC) against every strain is plotted in blue (A. viremic individ-
uals, B. individuals on-ART). The AUC profile of 3BNC117 against those same strains 
is plotted in red as a comparator. The neutralization profiles were compared by assess-
ing their Spearman rank correlation. p-values indicated in top right corner of graph 
(grey = n.s., red = significant). Bonferroni-corrected threshold: 0.0019. Full rank 










































































































































































































































p = 0.8922 p = 0.9786 p = 0.1013 p = 0.4930
p = 0.4561 p = 0.6138 p = 0.8632 p = 0.3103
p = 0.5785 p = 0.1955 p = 0.8690 p = 0.8517
Fig. S5., continued
Neutralization profile comparison of AUC change in 3BNC117-treated individuals 
with neutralization profile of 3BNC117. For each individual the individual’s AUC 
change (Wk24 - Day 0 AUC) against every strain is plotted in blue (A. viremic individ-
uals, B. individuals on-ART). The AUC profile of 3BNC117 against those same strains 
is plotted in red as a comparator. The neutralization profiles were compared by assess-
ing their Spearman rank correlation. p-values indicated in top right corner of graph 
(grey = n.s., red = significant). Bonferroni-corrected threshold: 0.0019. Full rank 
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Pairwise diversity over time (amino acid level). Scatter plots depicting pairwise amino 
acid sequence diversity of plasma env sequences on d0, and wk 4 (*wk6 for 2E5), 12 
and 24 after infusion. Each dot represents the pairwise genetic difference between two 
sequences at a given timepoint. Colored bars indicate median diversity, while black 
bars indicates the interquartile range. p-values were determined using a two-sample 
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Fig. S7. 
Viral evolution in subjects 2A3, 2C5, 2C4 and 2E2-2E5. Top. Maximum-likelihood 
phylogenetic trees of plasma-derived env sequences from respective subjects sampled 
on d0, wk4 (wk6 in case of 2E5), wk12 and wk24 after 3BNC117 infusion. Black 
asterisks indicate nodes with significant boostrap values (bootstrap support ≥ 70%). Bar 
graphs (middle) indicate the timepoints from which sequences were derived. Heat maps 
(right) show the 3BNC117 IC50, d0 IgG IC50 and wk 24 IgG IC50 values against autolo-
gous envs as indicated by colored stars. Bottom. Weblogo plots that illustrate amino 
acid changes in and directly adjacent to 3BNC117 contact residues over time. White 
boxes indicate that sequence matches to the d0 consensus, grey boxes indicate gaps in 
alignment. Colors indicate basic (dark blue) and acidic (red) residues and a turquoise 
“O” is used instead of “N” to indicate a potential N-glycosylation site. Logo plots were 
generated using LASSIE (28). + symbols indicate contact residues confirmed by two 
crystal structures (26, 27).
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Fig. S7., continued
Viral evolution in subjects 2A3, 2C5, 2C4 and 2E2-2E5. Top. Maximum-likelihood 
phylogenetic trees of plasma-derived env sequences from respective subjects sampled 
on d0, wk4 (wk6 in case of 2E5), wk12 and wk24 after 3BNC117 infusion. Black 
asterisks indicate nodes with significant boostrap values (bootstrap support ≥ 70%). Bar 
graphs (middle) indicate the timepoints from which sequences were derived. Heat maps 
(right) show the 3BNC117 IC50, d0 IgG IC50 and wk 24 IgG IC50 values against autolo-
gous envs as indicated by colored stars. Bottom. Weblogo plots that illustrate amino 
acid changes in and directly adjacent to 3BNC117 contact residues over time. White 
boxes indicate that sequence matches to the d0 consensus, grey boxes indicate gaps in 
alignment. Colors indicate basic (dark blue) and acidic (red) residues and a turquoise 
“O” is used instead of “N” to indicate a potential N-glycosylation site. Logo plots were 
generated using LASSIE (28). + symbols indicate contact residues confirmed by two 
crystal structures (26, 27).
Fig. S7., continued
Viral evolution in subjects 2A3, 2C5, 2C4 and 2E2-2E5. Top. Maximum-likelihood 
phylogenetic trees of plasma-derived env sequences from respective subjects sampled 
on d0, wk4 (wk6 in case of 2E5), wk12 and wk24 after 3BNC117 infusion. Black 
asterisks indicate nodes with significant boostrap values (bootstrap support ≥ 70%). Bar 
graphs (middle) indicate the timepoints from which sequences were derived. Heat maps 
(right) show the 3BNC117 IC50, d0 IgG IC50 and wk 24 IgG IC50 values against autolo-
gous envs as indicated by colored stars. Bottom. Weblogo plots that illustrate amino 
acid changes in and directly adjacent to 3BNC117 contact residues over time. White 
boxes indicate that sequence matches to the d0 consensus, grey boxes indicate gaps in 
alignment. Colors indicate basic (dark blue) and acidic (red) residues and a turquoise 
“O” is used instead of “N” to indicate a potential N-glycosylation site. Logo plots were 
generated using LASSIE (28). + symbols indicate contact residues confirmed by two 
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Fig. S7., continued
Viral evolution in subjects 2A3, 2C5, 2C4 and 2E2-2E5. Top. Maximum-likelihood 
phylogenetic trees of plasma-derived env sequences from respective subjects sampled 
on d0, wk4 (wk6 in case of 2E5), wk12 and wk24 after 3BNC117 infusion. Black 
asterisks indicate nodes with significant boostrap values (bootstrap support ≥ 70%). Bar 
graphs (middle) indicate the timepoints from which sequences were derived. Bottom. 
Weblogo plots that illustrate amino acid changes in and directly adjacent to 3BNC117 
contact residues over time. White boxes indicate that sequence matches to the d0 
consensus, grey boxes indicate gaps in alignment. Colors indicate basic (dark blue) and 
acidic (red) residues and a turquoise “O” is used instead of “N” to indicate a potential 
N-glycosylation site. Logo plots were generated using LASSIE (28). + symbols indicate 
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Fig. S7., continued
Viral evolution in subjects 2A3, 2C5, 2C4 and 2E2-2E5. Top. Maximum-likelihood 
phylogenetic trees of plasma-derived env sequences from respective subjects sampled 
on d0, wk4 (wk6 in case of 2E5), wk12 and wk24 after 3BNC117 infusion. Black 
asterisks indicate nodes with significant boostrap values (bootstrap support ≥ 70%). Bar 
graphs (middle) indicate the timepoints from which sequences were derived. Bottom. 
Weblogo plots that illustrate amino acid changes in and directly adjacent to 3BNC117 
contact residues over time. White boxes indicate that sequence matches to the d0 
consensus, grey boxes indicate gaps in alignment. Colors indicate basic (dark blue) and 
acidic (red) residues and a turquoise “O” is used instead of “N” to indicate a potential 
N-glycosylation site. Logo plots were generated using LASSIE (28). + symbols indicate 
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Fig. S7., continued 
Viral evolution in subjects 2A3, 2C5, 2C4 and 2E2-2E5. Top. Maximum-likelihood 
phylogenetic trees of plasma-derived env sequences from respective subjects sampled 
on d0, wk4 (wk6 in case of 2E5), wk12 and wk24 after 3BNC117 infusion. Black 
asterisks indicate nodes with significant boostrap values (bootstrap support ≥ 70%). Bar 
graphs (middle) indicate the timepoints from which sequences were derived. Bottom. 
Weblogo plots that illustrate amino acid changes in and directly adjacent to 3BNC117 
contact residues over time. White boxes indicate that sequence matches to the d0 
consensus, grey boxes indicate gaps in alignment. Colors indicate basic (dark blue) and 
acidic (red) residues and a turquoise “O” is used instead of “N” to indicate a potential 
N-glycosylation site. Logo plots were generated using LASSIE (28). + symbols indicate 
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Fig. S7., continued 
Viral evolution in subjects 2A3, 2C5, 2C4 and 2E2-2E5. Top. Maximum-likelihood 
phylogenetic trees of plasma-derived env sequences from respective subjects sampled 
on d0, wk4 (wk6 in case of 2E5), wk12 and wk24 after 3BNC117 infusion. Black 
asterisks indicate nodes with significant boostrap values (bootstrap support ≥ 70%). Bar 
graphs (middle) indicate the timepoints from which sequences were derived. For 2E5 
pink indicates wk4, dark purple indicates wk6 sequences. Bottom. Weblogo plots that 
illustrate amino acid changes in and directly adjacent to 3BNC117 contact residues over 
time. White boxes indicate that sequence matches to the d0 consensus, grey boxes 
indicate gaps in alignment. Colors indicate basic (dark blue) and acidic (red) residues 
and a turquoise “O” is used instead of “N” to indicate a potential N-glycosylation site. 
Logo plots were generated using LASSIE (28). + symbols indicate contact residues 
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Viral sequence evolution in subject 2A1. Amino acid highlighter plots of 2A1 plasma 
env sequences separated by group (A-D, Fig. 4) illustrate that viral selection in 2A1 
occurs mainly by ‘clade shifting’ with little sequence evolution within ‘clades’. Similar 
patterns of shifting groups of viruses are seen in 2A3 and 2C4 where tree structure is 
even more complex making clear-cut group analyses challenging. Horizontal lines 
represent individual sequences and tic marks denote amino acid differences from the 
respective d0 consensus sequence (cutoff >50% identity) of each group. The amino acid 
color code key is at the bottom right. Bars to the left indicate the timepoint that each 
sequence belongs to and is ordered chronologically within each group from top to 
bottom. Grey-green boxes demarcate variable loops and black/light blue tic marks 
below the plot indicate 3BNC117 amino acid and glycan contacts, respectively, as 
determined by two crystal structures (25, 26).
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Viral sequence evolution in subjects 2C5 and 2E1-2E5. Amino acid highlighter plot for 
each patient (2C5, 2E1-2E5) depicts sequence changes over time relative to respective 
d0 consensus (cutoff >50% identity). Horizontal lines represent individual sequences 
and tic marks denote amino acid differences from consensus sequence. Amino acid color 
code key is at bottom right. Grey-green boxes demarcate variable loops and black/light 
blue tic marks underneath plots indicate 3BNC117 amino acid and glycan contacts, 
respectively, as determined by two crystal structures (26, 27). In contrast to subjects 
2A1, 2A3 and 2C4, subjects 2C5 and 2E1-2E5 exhibit less complex phylogenies allow-
ing for more stringent calling of a single day0 consensus sequence.
Fig. S9., continued
Viral sequence evolution in subjects 2C5 and 2E1-2E5. Amino acid highlighter plot for 
each patient (2C5, 2E1-2E5) depicts sequence changes over time relative to respective 
d0 consensus (cutoff >50% identity). Horizontal lines represent individual sequences 
and tic marks denote amino acid differences from consensus sequence. Amino acid color 
code key is at bottom right. Grey-green boxes demarcate variable loops and black/light 
blue tic marks underneath plots indicate 3BNC117 amino acid and glycan contacts, 
respectively, as determined by two crystal structures (26, 27). In contrast to subjects 
2A1, 2A3 and 2C4, subjects 2C5 and 2E1-2E5 exhibit less complex phylogenies allow-
ing for more stringent calling of a single day0 consensus sequence.
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Viral sequence evolution in subjects 2C5 and 2E1-2E5. Amino acid highlighter plot for 
each patient (2C5, 2E1-2E5) depicts sequence changes over time relative to respective 
d0 consensus (cutoff >50% identity). Horizontal lines represent individual sequences 
and tic marks denote amino acid differences from consensus sequence. Amino acid color 
code key is at bottom right. Grey-green boxes demarcate variable loops and black/light 
blue tic marks underneath plots indicate 3BNC117 amino acid and glycan contacts, 
respectively, as determined by two crystal structures (26, 27). In contrast to subjects 
2A1, 2A3 and 2C4, subjects 2C5 and 2E1-2E5 exhibit less complex phylogenies allow-
ing for more stringent calling of a single day0 consensus sequence.
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Viral sequence evolution in subjects 2C5 and 2E1-2E5. Amino acid highlighter plot for 
each patient (2C5, 2E1-2E5) depicts sequence changes over time relative to respective 
d0 consensus (cutoff >50% identity). Horizontal lines represent individual sequences 
and tic marks denote amino acid differences from consensus sequence. Amino acid color 
code key is at bottom right. Grey-green boxes demarcate variable loops and black/light 
blue tic marks underneath plots indicate 3BNC117 amino acid and glycan contacts, 
respectively, as determined by two crystal structures (26, 27). In contrast to subjects 
2A1, 2A3 and 2C4, subjects 2C5 and 2E1-2E5 exhibit less complex phylogenies allow-
ing for more stringent calling of a single day0 consensus sequence.
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Viral sequence evolution in subjects 2C5 and 2E1-2E5. Amino acid highlighter plot for 
each patient (2C5, 2E1-2E5) depicts sequence changes over time relative to respective 
d0 consensus (cutoff >50% identity). Horizontal lines represent individual sequences 
and tic marks denote amino acid differences from consensus sequence. Amino acid color 
code key is at bottom right. Grey-green boxes demarcate variable loops and black/light 
blue tic marks underneath plots indicate 3BNC117 amino acid and glycan contacts, 
respectively, as determined by two crystal structures (26, 27). In contrast to subjects 
2A1, 2A3 and 2C4, subjects 2C5 and 2E1-2E5 exhibit less complex phylogenies allow-
ing for more stringent calling of a single day0 consensus sequence.
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Viral sequence evolution in subjects 2C5 and 2E1-2E5. Amino acid highlighter plot for 
each patient (2C5, 2E1-2E5) depicts sequence changes over time relative to respective 
d0 consensus (cutoff >50% identity). Horizontal lines represent individual sequences 
and tic marks denote amino acid differences from consensus sequence. Amino acid color 
code key is at bottom right. Grey-green boxes demarcate variable loops and black/light 
blue tic marks underneath plots indicate 3BNC117 amino acid and glycan contacts, 
respectively, as determined by two crystal structures (26, 27). In contrast to subjects 
2A1, 2A3 and 2C4, subjects 2C5 and 2E1-2E5 exhibit less complex phylogenies allow-
ing for more stringent calling of a single day0 consensus sequence.
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Full 3BNC117 contact site logo plots for subjects 2A1 and 2E1. Top. Weblogo plots that 
illustrate amino acid changes in and directly adjacent to 3BNC117 contact residues over 
time. White boxes indicate that sequence matches to the d0 consensus, grey boxes 
indicate gaps in alignment. Colors indicate basic (dark blue) and acidic (red) residues 
and a turquoise “O” is used instead of “N” to indicate a potential N-glycosylation site. 
Logo plots were generated using LASSIE (28). + symbols indicate 3BNC117 contact 
residues confirmed by two crystal structures (26, 27).
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Table S1A. 
Clinical characteristics of 3BNC117-treated subjects 
Subject ID 3BNC117 dose Age
















abs. CD4+ T 
cell count  
(day 0; 
cells/mm3)
abs. CD4+ T 
cell count  
(Week 24; 
cells/mm3)
2A1 1 mg/kg 35 11 ART naïve B 168 3210 2330 674 790
2A3 1 mg/kg 39 14 Off ART B 171 43650 2870 520 800
2A4 1 mg/kg 42 8 ART naïve B 167 5340 <20*** 607 671
2B1 3 mg/kg 20 1 Off ART ND 168 4090 <20*** 264* 335
2B2 3 mg/kg 48 20 DRV/r/TDF/FTC ND 167 100 <20 706 578
2B3 3 mg/kg 20 1 ART naïve B 168 38190 <20*** 777 627
2C2 10 mg/kg 51 12 ATV/r/3TC/ZDV ND 169 30 140 728 804
2C4 10 mg/kg 54 23 Off ART B 168 820 530 805 821
2C5 10 mg/kg 50 4 ART naïve B 168 9260 24240 245* 203
2D1 30 mg/kg 33 3 ART naïve B 168 53470 <20*** 980 885
2C1 30 mg/kg 51 17 Off ART B 168 47650 54950 1129 1026
2D3 30 mg/kg 33 0.5 ART naïve B 168 640 <20*** 618 482
2E1 30 mg/kg 21 2 ART naïve B 169 15780 16500 847 660
2E2 30 mg/kg 46 1.5 ART naïve B 169 6990 6590 513 480
2E3 30 mg/kg 23 1.5 ART naïve BF 168 22030 35200 590 850
2E4 30 mg/kg 38 1 ART naïve B 169 32220 69300 603 670
2E5 30 mg/kg 30 1 ART naïve B 169 3610 6110 532 600
5A1 10 mg/kg 28 6 EFV/TDF/FTC ND 168 <20 <20 814 661
5A2 10 mg/kg 58 19 EFV/TDF/FTC ND 168 <20 <20 660 619
5A3 10 mg/kg 54 18 EVG/c/FTC/TDF ND 168 <20 <20 1341 1203
5A4 10 mg/kg 53 5 EFV/TDF/FTC ND 168 <20 <20 466 574
5A5 10 mg/kg 41 4 EFV/TDF/FTC ND 168 <20 <20 924 624
5B1 30 mg/kg 58 28 EFV/TDF/FTC ND 168 <20 <20 654 760
5B2 30 mg/kg 53 19 EFV/ZDV/3TC ND 168 <20 <20 1065 1053
5B3 30 mg/kg 26 5 EFV/TDF/FTC ND 168 <20 <20 583 603
5B4 30 mg/kg 64 9 ATV/r/TDF/FTC ND 168 <20 <20 503 411
5B5 30 mg/kg 63 28 RAL/DRV/r/ETR ND 168 <20 <20 534 821
* Absolute CD4+ T cell count was 309 and 302 cells/mm3 at screening. ND - Not Determined
*** Start of ART (Weeks post infusion): 2A3 (24), 2A4 (12), 2B1 (8), 2B3 (12), 2D1 (20), 2D3 (8)
ART-abbreviations: DRV darunavir, TDF tenofovir, FTC emtricitabine, r ritonavir, ATV atazanavir, 3TC lamivudine, ZDV zidovudine,        EFV 
efavirenz, EVG elvitegravir, c cobicistat, RAL raltegravir, ETR etravirine
Table S1B. 
Clinical characteristics of untreated viremic subjects
Subject ID 3BNC117 dose Age
















abs. CD4+ T 
cell count  
(day 0; 
cells/mm3)
abs. CD4+ T 
cell count  
(Week 24; 
cells/mm3)
10518 / 44 24 / ND 182 38500 10000 643 536
10362 / 56 22 / ND 190 2380 3670 643 818
10112 / 42 20 / ND 171 7170 33500 513 551
10962 / 38 11 / ND 168 7808 14112 489 468
10223 / 44 20 / ND 196 4590 1300 473 444
10482 / 57 14 / ND 183 3690 2014 642 640
10210 / 49 16 / ND 189 3965 31495 546 412
10596 / 43 14 / ND 188 1607 2269 503 488
10138 / 47 16 / ND 196 17304 10149 536 532
10108 / 44 18 / ND 196 7810 37800 850 501
10275 / 36 17 / ND 181 24600 18220 643 648
10959 / 50 15 / ND 189 303200 61000 760 621
10367 / 44 20 / ND 195 432 1460 579 605
10469 / 35 13 / ND 188 24000 573 1150 682
10410 / 46 4 / ND 182 42920 62740 522 403
10397 / 39 20 / ND 182 5327 13520 495 500
10292 / 42 28 / ND 187 2152 3985 624 642
10802 / 40 2 / ND 187 150 629 380 302
10099 / 35 12 / ND 187 9095 12160 669 717
10930 / 52 17 / ND 188 101500 263700* 562 448*
10417 / 36 5 / ND 56 16070 41311 328 N/A
10690 / 30 2 / ND 112 17820 97982 361 N/A
10257 / 32 6 / ND 196 255 52091 449** 397
10587 / 28 1 / ND 117 222465 772642 377 N/A
10169 / 34 12 / ND 617 12423 34836 476 N/A
10160 / 34 0.5 / ND 106 3984 5495 337 N/A
10811 / 43 20 / ND 215 2520 5610 307 377
10239 / 46 3 / ND 245 2660 8659 561 N/A
10814 / 45 5 / ND 181 45000 33900 567 430
10100 / 37 0.2 / ND 76 32360 13014 689 N/A
10779 / 33 4 / ND 89 14029 25234 512 N/A
10785 / 33 1 / ND 218 7438 148000 550 314
10489 / 41 6 / ND 169 41100 1750 588 N/A
10082 / 40 9 / ND 209 37600 104000 469 N/A
10914 / 48 9 / ND 224 25000 21300 383 N/A
10689 / 28 0.5 / ND 188 2600 137000 426*** 336
* Absolute CD4+ T cell count and HIV-RNA level were measured from a different sample from a timepoint 2 weeks later.
** Absolute CD4+ T cell count was measured from a different sample from a timepoint 2 years earlier. ND - Not Determined. N/A - Not Available
*** Absolute CD4+ T cell count was measured from a different sample from a timepoint 3 months earlier. 
Table S2. 
Autologous neutralization data of patient IgG against PBMC co-culture virus
Subject ID IgG tested IC50 (µg/ml) AUC  IC50 (µg/ml) AUC 
D0 IgG >500 0.071 >500 0.11
w24 IgG >500 0.209 686.4 0.324
0 - 25 µg/ml
D0 IgG >500 0.571 >500 0 25 -100 µg/ml
w24 IgG 385.6 0.972 >500 0.115 100 - 400 µg/ml  
400 - 500 µg/ml
D0 IgG >500 0.203 >500 0.28 >500 µg/ml
w24 IgG >500 0.505 286.5 0.659
D0 IgG >500 0.354 >500 0.143
w24 IgG 287.0 1.022 226.3 0.807
D0 IgG >500 0 >500 0
w24 IgG 417.8 0.857 311.7 0.593
D0 IgG >500 0.209 >500 0.319
w24 IgG 417.6 0.401 194.5 0.84
D0 IgG >500 0.527 >500 0.308
w24 IgG 96.7 1.335 269.3 0.615
D0 IgG >500 0.033 >500 0.005
w24 IgG >500 0.038 >500 0.055
D0 IgG >500 0.181 >500 0.099
w24 IgG 462.6 0.456 >500 0.253




















Panel of pseudoviruses used to determine neutralizing activity
HIV-1 Strains Clade Tier*
246-F3_C10_2 AC Tier 2
25710-2.43 C Tier 2
BaL.26 B Tier 1B
Ce1176_A3 C Tier 2
CNE55 AE Tier 2
CNE8 AE Tier 2
Q259.d2.17 A Tier 2
Q769.d22 A Tier 2
Q842.d12 A Tier 2
TRO.11 B Tier 2
X1632_S2_B10 G Tier 2
YU2.DG B Tier 2
ZM135M.PL10a C Tier 2
*Tier classification for standard TZM-bl, based on (21, 43) 
Table S4A. 
Heterologous TZM.bl neutralization data of purified patient IgG (IC50 values, µg/ml)
Viremic control patients
Heterologous 
Strain Clade Day 0 Day 0 Day 0 Day 0 Day 0
YU2.DG B >500 >500 >500 >500 28.7 45.6 69.1 65.2 117.0 130.9
BaL.26 B 43.9 42.8 18.6 19.0 4.4 8.9 9.2 8.1 29.1 26.1
Q769.d22 A1 >500 >500 >500 >500 9.5 23.3 69.4 54.9 75.8 69.8
Q259.d2.17 A1 >500 >500 >500 >500 210.9 233.6 132.0 127.4 232.5 176.5
Q842.d12 A1 >500 >500 >500 >500 10.8 26.7 16.3 17.5 24.4 26.3
ZM135M.PL10a C >500 >500 >500 >500 183.1 94.6 233.4 124.8 192.1 490.7
25710-2.43 C 373.9 >500 >500 >500 22.8 42.0 98.7 92.3 79.5 95.6
CNE8 AE >500 >500 >500 >500 115.4 233.3 163.9 136.4 92.4 84.2
TRO.11 B >500 >500 >500 >500 19.9 30.0 28.9 27.9 41.1 57.4
X1632_S2_B10 G >500 >500 >500 >500 >368 >500 258.4 394.5 44.3 70.8
Ce1176_A3 C >500 >500 >500 >500 28.5 68.7 204.2 161.7 89.8 75.6
246-F3_C10_2 AC >500 >500 >500 >500 77.4 109.7 278.6 189.5 120.3 123.2
CNE55 AE >500 >500 >500 >500 N/A 196.1 93.1 90.7 34.7 57.1
Heterologous 
Strain Clade Day 0 Day 0 Day 0 Day 0 Day 0
YU2.DG B >500 >500 384.0 277.2 67.6 83.2 20.9 23.5 54.8 45.6
BaL.26 B 58.9 52.8 19.6 16.5 9.4 8.6 3.4 3.3 1.9 2.1
Q769.d22 A1 >500 >500 >500 >500 >500 >500 38.0 31.4 4.3 5.1
Q259.d2.17 A1 >500 >500 >500 >500 360.2 >500 291.0 371.5 7.2 7.7
Q842.d12 A1 >500 >500 348.5 393.9 89.4 234.6 7.7 11.2 5.2 6.7
ZM135M.PL10a C >500 >500 >500 >500 >500 >500 >500 >500 52.5 37.7
25710-2.43 C >500 >500 480.4 472.1 32.7 61.4 248.2 214.1 14.3 15.1
CNE8 AE >500 >500 >500 >500 >500 >500 327.4 384.8 27.1 29.9
TRO.11 B 276.6 >500 >500 >500 123.2 91.2 15.0 19.0 5.4 6.4
X1632_S2_B10 G >500 >500 >500 >500 271.8 228.1 24.2 33.2 6.7 8.6
Ce1176_A3 C >500 >500 >500 >500 60.3 72.7 >500 >500 94.9 94.1
246-F3_C10_2 AC >500 >500 >500 >500 >500 >500 193.3 304.6 23.0 22.8
CNE55 AE >500 >500 >500 >500 >500 >500 189.1 216.5 18.1 21.1
Heterologous 
Strain Clade Day 0 Day 0 Day 0 Day 0 Day 0
YU2.DG B >500 >500 41.8 41.6 24.8 22.0 439.4 431.5 >500 >500
BaL.26 B 27.1 34.2 10.7 11.8 5.0 6.0 26.4 35.6 56.0 32.0
Q769.d22 A1 >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
Q259.d2.17 A1 >500 >500 >500 >500 166.5 222.0 89.9 139.0 >500 >500
Q842.d12 A1 >500 >500 16.3 17.8 170.9 >500 295.7 373.6 >500 >500
ZM135M.PL10a C >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
25710-2.43 C >500 >500 320.5 334.3 23.7 24.1 302.2 273.4 >500 276.4
CNE8 AE >500 >500 493.4 428.4 >500 >500 >500 >500 >500 >500
TRO.11 B >500 >500 51.1 45.2 11.3 10.5 >500 >500 >500 >500
X1632_S2_B10 G >500 >500 136.9 105.6 102.5 90.4 >500 >500 >500 >500
Ce1176_A3 C >500 >500 >500 >500 20.4 21.6 >500 >500 >500 >500
246-F3_C10_2 AC >500 >500 227.2 209.5 36.8 46.0 >500 >500 >500 >500
CNE55 AE >500 >500 51.0 60.9 >500 >500 >500 >500 >500 >500
Heterologous 
Strain Clade Day 0 Day 0 Day 0
YU2.DG B 160.4 133.8 298.1 279.9 >500 >500
BaL.26 B 7.4 8.0 17.7 21.1 >500 >500
Q769.d22 A1 >500 >500 >500 >500 >500 >500
Q259.d2.17 A1 >500 >500 >500 >500 >500 >500
Q842.d12 A1 >500 438.3 313.0 273.4 >500 >500
ZM135M.PL10a C >500 >500 >500 >500 >500 >500
25710-2.43 C 182.4 320.5 429.6 445.7 >500 >500
CNE8 AE >500 >500 378.7 485.3 >500 >500
TRO.11 B 422.6 422.4 482.1 >500 >500 >500 0 - 25 µg/ml
X1632_S2_B10 G >500 >500 >500 >500 >500 >500 25 -100 µg/ml
Ce1176_A3 C >500 >500 >500 >500 56.4 61.9 100 - 400 µg/ml 
246-F3_C10_2 AC >500 >500 >500 >500 >500 >500 400 - 500 µg/ml













































10482 10210 10596 10138
Table S4A. 
Heterologous TZM.bl neutralization data of purified patient IgG (IC50 values, µg/ml), continued
Heterologous 
Strain Clade Day 0 Day 0 Day 0 Day 0 Day 0
YU2.DG B >500 >500 102.2 122.5 405.2 >500 95.2 92.9 211.3 169.4
BaL.26 B 52.3 42.1 15.8 16.8 6.4 5.5 24.2 33.4 25.7 26.2
Q769.d22 A1 >500 >500 204.5 343.0 >500 >500 >500 >500 >500 >500
Q259.d2.17 A1 >500 >500 199.1 250.1 >500 >500 >500 >500 295.5 183.0
Q842.d12 A1 >500 >500 61.8 77.1 333.4 301.8 455.4 366.8 136.0 70.2
ZM135M.PL10a C >500 >500 >500 >500 219.6 133.7 >500 >500 254.0 155.6
25710-2.43 C 432.6 244.7 235.7 326.7 161.8 90.7 226.9 202.7 169.4 94.1
CNE8 AE 443.1 >500 29.6 39.2 48.5 32.9 365.6 295.1 150.2 117.5
TRO.11 B 187.5 198.6 81.9 122.4 81.7 68.8 174.4 166.6 67.7 62.2
X1632_S2_B10 G >500 >500 54.4 109.2 >500 >500 228.0 122.1 369.1 175.5
Ce1176_A3 C >500 >500 340.1 405.1 367.7 445.0 363.8 347.3 >500 >500
246-F3_C10_2 AC >500 >500 56.4 61.9 >500 >500 >500 >500 >500 >500
CNE55 AE >500 >500 87.7 83.6 476.1 453.9 >500 >500 >500 >500
Heterologous 
Strain Clade Day 0 Day 0 Day 0 Day 0 Day 0
YU2.DG B >500 >500 29.2 49.5 267.5 396.7 325.0 389.9 >500 >500
BaL.26 B 44.4 50.8 4.7 6.4 28.4 28.2 80.0 71.8 55.2 75.7
Q769.d22 A1 140.5 276.7 25.2 39.9 >500 >500 >500 498.6 >500 >500
Q259.d2.17 A1 >500 >500 72.2 102.9 >500 >500 >500 >500 >500 >500
Q842.d12 A1 252.5 194.6 21.2 33.5 >500 >500 476.7 146.2 >500 >500
ZM135M.PL10a C >500 >500 67.4 163.2 >500 >500 >500 >500 >500 >500
25710-2.43 C 377.1 416.7 74.2 37.1 199.7 300.0 254.5 84.6 245.7 326.5
CNE8 AE >500 >500 45.7 67.3 >500 >500 >500 >500 >500 >500
TRO.11 B 66.0 102.2 13.9 16.1 52.4 72.5 294.6 71.8 >500 >500
X1632_S2_B10 G >500 >500 68.2 41.3 >500 >500 >500 >500 >500 >500
Ce1176_A3 C >500 448.5 96.3 150.0 301.2 438.5 426.7 117.2 >500 >500
246-F3_C10_2 AC >500 >500 122.8 245.4 >500 >500 >500 278.4 >500 >500
CNE55 AE >500 311.7 75.2 100.2 >500 >500 472.9 255.5 >500 >500
Heterologous 
Strain Clade Day 0 Day 0 Day 0 Day 0 Day 0
YU2.DG B >500 >500 >500 >500 >500 >500 >500 >500 221.2 239.7
BaL.26 B 126.4 180.7 77.5 96.4 35.0 26.8 23.4 24.6 13.8 20.9
Q769.d22 A1 >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
Q259.d2.17 A1 >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
Q842.d12 A1 >500 >500 >500 >500 >500 >500 473.0 >500 >500 >500
ZM135M.PL10a C >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
25710-2.43 C >500 >500 >500 >500 >500 >500 149.9 151.3 399.0 360.7
CNE8 AE 228.4 233.6 >500 >500 205.3 310.0 >500 >500 >500 >500
TRO.11 B 134.6 175.1 >500 >500 >500 >500 >500 >500 59.2 73.2
X1632_S2_B10 G >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
Ce1176_A3 C >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
246-F3_C10_2 AC >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
CNE55 AE >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
Heterologous 
Strain Clade Day 0 Day 0 Day 0
YU2.DG B >500 >500 170.5 >500 >500 >500
BaL.26 B 34.2 38.8 29.7 77.8 29.0 43.2
Q769.d22 A1 >500 >500 >500 >500 >500 >500
Q259.d2.17 A1 >500 >500 >500 >500 >500 >500
Q842.d12 A1 >500 >500 >500 >500 >500 >500
ZM135M.PL10a C >500 >500 209.9 419.4 >500 >500
25710-2.43 C >500 >500 213.9 456.7 488.1 419.1
CNE8 AE >500 >500 276.4 >500 >500 >500
TRO.11 B 487.1 >500 307.7 >500 >500 >500 0 - 25 µg/ml
X1632_S2_B10 G >500 >500 >500 >500 >500 >500 25 -100 µg/ml
Ce1176_A3 C >500 >500 329.3 >500 >500 >500 100 - 400 µg/ml  
246-F3_C10_2 AC >500 >500 >500 >500 >500 >500 400 - 500 µg/ml















































Heterologous TZM.bl neutralization data of purified patient IgG (IC50 values, µg/ml), continued
3BNC117-treated viremic patients
Heterologous 
Strain Clade Day -7 Week 24 Day 0 Week 24 Day -7 Week 24 Day -7 Week 24 Day -7 Week 24
YU2.DG B 24.9 22.2 >500 363.4 >500 >500 >500 >500 >500 >500
BaL.26 B 3.3 3.2 28.4 18.9 89.5 71.3 135.0 164.8 365.9 310.8
Q769.d22 A1 102.6 97.0 >500 19.4 >500 >500 >500 >500 >500 >500
Q259.d2.17 A1 170.9 70.4 92.5 84.7 >500 >500 >500 >500 >500 >500
Q842.d12 A1 22.2 18.3 475.0 417.8 >500 >500 >500 >500 >500 >500
ZM135M.PL10a C >500 234.5 >500 >500 >500 >500 >500 >500 >500 >500
25710-2.43 C >500 324.1 110.8 136.0 >500 >500 >500 >500 >500 >500
CNE8 AE >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
TRO.11 B 137.7 52.9 218.6 203.0 >500 >500 >500 >500 >500 495.5
X1632_S2_B10 G 65.1 48.3 >500 >500 >500 >500 >500 >500 >500 >500
Ce1176_A3 C >500 >500 482.2 446.7 >500 >500 >500 >500 >500 >500
246-F3_C10_2 AC N/A 297.2 445.4 283.7 N/A >500 N/A >500 N/A >500
CNE55 AE >500 204.8 >500 >500 >500 >500 >500 >500 >500 >500
Heterologous 
Strain Clade Day -7 Week 24 Day -7 Week 24 Day 0 Week 24 Day -7 Week 24 Day -7 Week24
YU2.DG B 120.6 69.8 >500 >500 >500 >500 >500 >500 >500 >500
BaL.26 B 43.0 15.7 40.2 15.1 114.6 69.4 111.2 51.1 >500 >500
Q769.d22 A1 >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
Q259.d2.17 A1 >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
Q842.d12 A1 82.0 86.7 >500 >500 >500 >500 >500 423.1 >500 369.1
ZM135M.PL10a C >500 419.5 >500 225.8 >500 >500 >500 >500 >500 >500
25710-2.43 C 241.8 49.6 305.9 159.6 >500 >500 426.3 125.4 >500 >500
CNE8 AE 325.3 83.3 >500 240.4 >500 >500 >500 >500 >500 >500
TRO.11 B 69.8 13.3 >500 316.7 >500 >500 >500 486.2 >500 >500
X1632_S2_B10 G >500 378.2 >500 >500 >500 >500 >500 >500 >500 >500
Ce1176_A3 C >500 79.0 >500 >500 >500 >500 >500 >500 >500 >500
246-F3_C10_2 AC N/A 190.1 N/A >500 >500 >500 N/A >500 >500 >500
CNE55 AE >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
Heterologous 
Strain Clade Day 0 Week 24 Day 0 Week 24 Day 0 Week 24 Day 0 Week 24 Day 0 Week 24
YU2.DG B >500 >500 >500 >500 >500 >500 >500 495.7 >500 >500
BaL.26 B 87.4 41.1 28.9 16.8 85.2 24.2 103.0 87.7 393.8 66.1
Q769.d22 A1 407.3 181.7 >500 >500 >500 >500 >500 >500 >500 >500
Q259.d2.17 A1 >500 >500 >500 >500 >500 >500 >500 366.6 >500 480.4
Q842.d12 A1 >500 >500 >500 >500 >500 >500 467.2 333.4 >500 463.1
ZM135M.PL10a C >500 >500 >500 >500 >500 >500 366.3 495.1 >500 >500
25710-2.43 C 439.1 397.9 >500 >500 >500 471.6 148.4 158.7 >500 >500
CNE8 AE >500 >500 >500 >500 >500 >500 177.8 98.5 >500 >500
TRO.11 B 483.4 135.8 >500 >500 >500 >500 188.4 193.4 >500 >500
X1632_S2_B10 G >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
Ce1176_A3 C >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
246-F3_C10_2 AC >500 >500 >500 >500 >500 >500 277.1 483.5 >500 >500
CNE55 AE >500 >500 NT >500 >500 >500 >500 >500 >500 >500
0 - 25 µg/ml
25 -100 µg/mll
100 - 400 µg/ml  











Heterologous TZM.bl neutralization data of purified patient IgG (IC50 values, µg/ml), continued
3BNC117-treated patients on-ART
Heterologous 
Strain Clade Day 0 Week 24 Day 0 Week 24 Day 0 Week 24 Day 0 Week 24 Day 0 Week 24
YU2.DG B >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
BaL.26 B >500 >500 155.0 177.1 83.9 27.3 >500 404.5 >500 >500
Q769.d22 A1 >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
Q259.d2.17 A1 >500 >500 >500 >500 >500 430.6 >500 >500 >500 >500
Q842.d12 A1 >500 >500 >500 >500 >500 388.4 >500 492.9 >500 >500
ZM135M.PL10a C >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
25710-2.43 C >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
CNE8 AE >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
TRO.11 B >500 >500 >500 >500 >500 416.3 >500 >500 >500 >500
X1632_S2_B10 G >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
Ce1176_A3 C >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
246-F3_C10_2 AC >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
CNE55 AE >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
Heterologous 
Strain Clade Day 0 Week 24 Day 0 Week 24 Day 0 Week 24 Day 0 Week 24 Day 0 Week 24
YU2.DG B >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
BaL.26 B 129.2 134.1 127.9 152.5 >500 >500 66.8 46.4 124.8 89.5
Q769.d22 A1 >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
Q259.d2.17 A1 >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
Q842.d12 A1 >500 >500 >500 435.0 >500 >500 >500 >500 359.3 298.1
ZM135M.PL10a C >500 >500 >500 >500 >500 >500 >500 >500 >500 460.0
25710-2.43 C >500 >500 >500 >500 >500 >500 >500 >500 497.9 497.9
CNE8 AE >500 >500 >500 >500 >500 >500 >500 >500 >500 219.8
TRO.11 B >500 >500 >500 >500 >500 >500 >500 >500 >500 487.3
X1632_S2_B10 G >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
Ce1176_A3 C >500 >500 >500 >500 >500 >500 >500 >500 >500 >500
246-F3_C10_2 AC >500 >500 >500 >500 >500 >500 >500 >500 >500 279.2
CNE55 AE >500 >500 >500 >500 >500 >500 >500 >500 >500 381.2
Heterologous 
Strain Clade Day -7 Week 24 Day -7 Week 24
YU2.DG B >500 >500 >500 >500
BaL.26 B 237.0 231.1 134.3 75.8
Q769.d22 A1 >500 >500 >500 >500
Q259.d2.17 A1 >500 >500 >500 >500
Q842.d12 A1 >500 >500 >500 >500
ZM135M.PL10a C >500 >500 >500 >500
25710-2.43 C >500 >500 >500 >500
CNE8 AE >500 >500 >500 >500
TRO.11 B >500 >500 >500 353.6 0 - 25 µg/ml  
X1632_S2_B10 G >500 >500 >500 >500 25 -100 µg/ml  
Ce1176_A3 C >500 >500 >500 >500 100 - 400 µg/ml  
246-F3_C10_2 AC N/A >500 N/A >500 400 - 500 µg/ml  










Heterologous TZM.bl neutralization data of purified patient IgG (AUC)
Viremic control patients
Heterologous 
Strain Clade Day 0 Day 0 Day 0 Day 0 Day 0
YU2.DG B 0.24 0.18 0.09 0.13 2.08 1.90 1.43 1.51 1.13 1.09
BaL.26 B 1.79 1.96 2.61 2.64 3.30 3.08 3.13 3.19 2.39 2.36
Q769.d22 A1 0.17 0.40 0.37 0.24 2.70 2.49 1.57 1.60 1.52 1.41
Q259.d2.17 A1 0.03 0.19 0.05 0.07 0.73 0.71 1.11 1.06 0.79 0.87
Q842.d12 A1 0.31 0.27 0.16 0.51 2.77 2.44 2.80 2.70 2.52 2.49
ZM135M.PL10a C 0.02 0.31 0.05 0.13 0.87 1.31 0.79 1.28 0.93 0.71
25710-2.43 C 0.76 0.52 0.32 0.29 2.32 1.98 1.18 1.36 1.36 1.34
CNE8 AE 0.00 0.00 0.00 0.04 1.01 0.66 0.88 1.04 1.43 1.47
TRO.11 B 0.09 0.43 0.23 0.22 2.33 2.29 2.32 2.21 2.01 1.70
X1632_S2_B10 G 0.32 0.75 0.58 0.15 0.39 0.64 1.09 0.91 1.98 1.61
Ce1176_A3 C 0.21 0.09 0.35 0.07 1.94 1.65 0.84 0.99 1.43 1.58
246-F3_C10_2 AC 0.00 0.04 0.03 0.09 1.27 1.16 0.83 0.81 1.12 1.15
CNE55 AE 0.00 0.23 0.26 0.00 N/A N/A 1.41 1.31 2.13 1.68
Heterologous 
Strain Clade Day 0 Day 0 Day 0 Day 0 Day 0
YU2.DG B 0.06 0.09 0.51 0.64 1.51 1.46 2.64 2.55 1.73 1.84
BaL.26 B 1.75 1.75 2.54 2.78 3.09 3.08 3.59 3.54 3.75 3.69
Q769.d22 A1 0.29 0.63 0.41 0.08 0.34 0.25 1.90 1.83 3.46 3.36
Q259.d2.17 A1 0.18 0.18 0.40 0.26 0.71 0.23 0.66 0.68 3.28 3.26
Q842.d12 A1 0.59 0.49 0.90 0.89 1.40 1.03 3.20 3.03 3.38 3.19
ZM135M.PL10a C 0.13 0.09 0.38 0.46 0.73 0.36 0.68 0.83 1.85 1.92
25710-2.43 C 0.54 0.72 0.46 0.58 2.20 1.71 0.81 0.79 2.74 2.72
CNE8 AE 0.04 0.06 0.00 0.04 0.10 0.07 0.48 0.40 2.34 2.26
TRO.11 B 0.93 0.95 0.73 0.58 1.20 1.47 2.70 2.54 3.38 3.27
X1632_S2_B10 G 0.20 0.02 0.36 0.08 0.73 1.13 2.32 2.16 3.21 3.12
Ce1176_A3 C 0.31 0.24 0.59 0.35 1.76 1.53 0.15 0.34 1.28 1.46
246-F3_C10_2 AC 0.14 0.13 0.19 0.19 0.49 0.19 0.92 0.65 2.54 2.53
CNE55 AE 0.14 0.15 0.28 0.05 0.00 0.00 1.19 1.01 2.68 2.50
Heterologous 
Strain Clade Day 0 Day 0 Day 0 Day 0 Day 0
YU2.DG B 0.05 0.16 2.02 2.04 2.50 2.58 0.66 0.72 0.21 0.13
BaL.26 B 2.32 2.19 3.02 2.99 3.38 3.37 2.32 2.16 1.69 2.24
Q769.d22 A1 0.10 0.40 0.40 0.45 0.35 0.23 0.31 0.47 0.00 0.00
Q259.d2.17 A1 0.14 0.09 0.23 0.21 0.93 0.74 1.35 1.03 0.00 0.01
Q842.d12 A1 0.41 0.55 2.83 2.76 1.16 0.55 0.71 0.73 0.49 0.33
ZM135M.PL10a C 0.35 0.48 0.38 0.31 0.78 0.34 0.21 0.12 0.21 0.18
25710-2.43 C 0.46 0.40 0.58 0.57 2.48 2.46 0.86 0.97 0.41 1.08
CNE8 AE 0.02 0.00 0.23 0.34 0.14 0.22 0.08 0.08 0.00 0.00
TRO.11 B 0.24 0.27 1.83 1.86 3.03 3.07 0.92 0.82 0.00 0.03
X1632_S2_B10 G 0.20 0.22 1.07 1.19 1.26 1.41 0.69 0.65 0.29 0.23
Ce1176_A3 C 0.44 0.55 0.25 0.20 2.61 2.59 0.67 0.75 0.05 0.50
246-F3_C10_2 AC 0.17 0.11 0.76 0.85 2.06 1.88 0.19 0.19 0.14 0.27
CNE55 AE 0.42 0.05 1.81 1.74 0.69 0.27 0.45 0.11 0.00 0.17
Heterologous 
Strain Clade Day 0 Day 0 Day 0
YU2.DG B 0.90 1.04 0.60 0.65 0.00 0.00
BaL.26 B 3.15 3.16 2.68 2.55 0.11 0.00
Q769.d22 A1 0.16 0.74 0.20 0.00 0.18 0.11
Q259.d2.17 A1 0.00 0.00 0.19 0.19 0.02 0.02
Q842.d12 A1 0.41 0.60 0.63 0.66 0.32 0.36
ZM135M.PL10a C 0.02 0.00 0.00 0.00 0.01 0.08
25710-2.43 C 0.96 0.70 0.32 0.31 0.03 0.18
CNE8 AE 0.21 0.25 0.52 0.46 0.06 0.08
TRO.11 B 0.39 0.60 0.71 0.43 0.00 0.07
X1632_S2_B10 G 0.36 0.65 0.74 0.47 0.00 0.02 > 2
Ce1176_A3 C 0.14 0.19 0.15 0.16 1.82 1.75 1-2
246-F3_C10_2 AC 0.02 0.01 0.05 0.18 0.00 0.02 0.5 - 1
CNE55 AE 0.09 0.14 0.09 0.02 0.33 0.21 0 - 0.5
10518 10362 10112 10962 10223










































Heterologous TZM.bl neutralization data of purified patient IgG (AUC), continued
10257
Heterologous 
Strain Clade Day 0 Day 0 Day 0 Day 0 Day 0
YU2.DG B 0.07 0.09 1.24 1.08 0.48 0.51 1.31 1.37 0.75 0.83
BaL.26 B 1.81 1.95 2.77 2.72 3.24 3.31 2.38 2.16 2.44 2.40
Q769.d22 A1 0.00 0.07 1.27 1.06 0.21 0.08 0.20 0.52 0.26 0.18
Q259.d2.17 A1 0.04 0.06 0.86 0.60 0.19 0.13 0.03 0.09 0.50 0.87
Q842.d12 A1 0.26 0.39 1.85 1.61 0.59 1.03 0.43 0.63 1.26 1.69
ZM135M.PL10a C 0.06 0.06 0.08 0.01 0.76 1.26 0.19 0.15 0.69 1.24
25710-2.43 C 0.38 0.64 0.65 0.54 1.01 1.41 0.73 0.77 0.97 1.48
CNE8 AE 0.56 0.37 2.33 2.18 1.88 2.21 0.54 0.54 0.99 1.18
TRO.11 B 0.81 0.85 1.53 1.19 1.48 1.64 1.06 1.02 1.69 1.77
X1632_S2_B10 G 0.09 0.00 1.68 1.29 0.46 0.30 0.81 1.18 0.61 0.90
Ce1176_A3 C 0.67 0.41 0.82 0.73 0.68 0.69 0.60 0.64 0.28 0.31
246-F3_C10_2 AC 0.11 0.01 1.82 1.75 0.28 0.31 0.07 0.08 0.13 0.21
CNE55 AE 0.03 0.09 1.57 1.54 0.64 0.43 0.18 0.14 0.41 0.08
Heterologous 
Strain Clade Day 0 Day 0 Day 0 Day 0 Day 0
YU2.DG B 0.40 0.29 2.34 1.98 0.64 0.51 0.43 0.48 0.21 0.20
BaL.26 B 1.95 1.83 3.46 3.36 2.30 2.33 1.54 1.53 1.66 1.53
Q769.d22 A1 1.38 0.79 2.36 2.04 0.44 0.28 0.21 0.62 0.12 0.49
Q259.d2.17 A1 0.18 0.21 1.51 1.30 0.16 0.03 0.04 0.10 0.12 0.01
Q842.d12 A1 0.75 0.87 2.55 2.16 0.26 0.20 0.39 1.10 0.23 0.22
ZM135M.PL10a C 0.15 0.05 1.70 0.98 0.40 0.24 0.06 0.19 0.32 0.16
25710-2.43 C 0.49 0.42 1.48 2.07 0.82 0.63 0.69 1.40 0.70 0.54
CNE8 AE 0.28 0.35 1.96 1.62 0.41 0.32 0.07 0.25 0.18 0.12
TRO.11 B 1.66 1.38 2.85 2.58 1.70 1.57 0.93 1.55 0.29 0.26
X1632_S2_B10 G 0.52 0.49 1.60 1.96 0.40 0.71 0.29 0.16 0.35 0.19
Ce1176_A3 C 0.27 0.44 1.47 1.14 0.83 0.69 0.66 1.31 0.29 0.19
246-F3_C10_2 AC 0.04 0.07 1.22 0.62 0.08 0.07 0.16 0.75 0.21 0.10
CNE55 AE 0.63 0.57 1.61 1.46 0.40 0.59 0.79 1.07 0.41 0.29
Heterologous 
Strain Clade Day 0 Day 0 Day 0 Day 0 Day 0
YU2.DG B 0.09 0.25 0.00 0.00 0.02 0.00 0.25 0.15 0.70 0.63
BaL.26 B 1.21 0.99 1.36 1.30 2.81 2.54 2.19 2.05 2.11 2.31
Q769.d22 A1 0.30 0.10 0.00 0.03 0.00 0.07 0.17 0.07 0.00 0.09
Q259.d2.17 A1 0.16 0.10 0.00 0.07 0.00 0.00 0.18 0.10 0.00 0.05
Q842.d12 A1 0.09 0.13 0.00 0.21 0.01 0.04 0.38 0.40 0.12 0.15
ZM135M.PL10a C 0.20 0.34 0.00 0.00 0.25 0.25 0.29 0.25 0.11 0.10
25710-2.43 C 0.18 0.23 0.08 0.18 0.44 0.38 1.14 1.14 0.47 0.60
CNE8 AE 0.79 0.81 0.02 0.16 0.70 0.46 0.18 0.18 0.00 0.04
TRO.11 B 1.11 1.05 0.00 0.02 0.30 0.18 0.30 0.21 1.68 1.59
X1632_S2_B10 G 0.15 0.36 0.00 0.00 0.09 0.06 0.31 0.23 0.00 0.05
Ce1176_A3 C 0.29 0.35 0.20 0.01 0.08 0.19 0.36 0.38 0.21 0.29
246-F3_C10_2 AC 0.15 0.21 0.38 0.08 0.12 0.11 0.31 0.31 0.08 0.14
CNE55 AE 0.19 0.14 0.02 0.87 0.00 0.19 0.22 0.12 0.00 0.00
Heterologous 
Strain Clade Day 0 Day 0 Day 0
YU2.DG B 0.08 0.00 0.88 0.28 0.10 0.08
BaL.26 B 2.46 2.37 2.31 1.45 2.33 1.97
Q769.d22 A1 0.13 0.01 0.08 0.20 0.51 0.22
Q259.d2.17 A1 0.06 0.04 0.02 0.01 0.26 0.25
Q842.d12 A1 0.06 0.00 0.13 0.04 0.44 0.35
ZM135M.PL10a C 0.12 0.15 0.77 0.46 0.30 0.40
25710-2.43 C 0.11 0.07 0.92 0.52 0.44 0.45
CNE8 AE 0.00 0.00 0.62 0.25 0.01 0.00
TRO.11 B 0.45 0.20 0.53 0.20 0.16 0.24
X1632_S2_B10 G 0.13 0.13 0.08 0.00 0.03 0.00 > 2
Ce1176_A3 C 0.05 0.02 0.60 0.27 0.30 0.30 1-2
246-F3_C10_2 AC 0.10 0.11 0.18 0.10 0.24 0.31 0.5 - 1
















































Heterologous TZM.bl neutralization data of purified patient IgG (AUC), continued
3BNC117-treated viremic patients
Heterologous 
Strain Clade Day -7 Week 24 Day 0 Week 24 Day -7 Week 24 Day -7 Week 24 Day -7 Week 24
YU2.DG B 2.51 2.60 0.21 0.61 0.09 0.37 0.03 0.00 0.00 0.02
BaL.26 B 3.72 3.70 2.35 2.55 1.41 1.64 1.03 0.94 0.41 0.52
Q769.d22 A1 1.72 1.64 0.19 2.40 0.00 0.06 0.07 0.00 0.00 0.01
Q259.d2.17 A1 0.91 1.76 1.02 1.61 0.01 0.20 0.05 0.51 0.00 0.20
Q842.d12 A1 2.53 2.67 0.36 0.56 0.04 0.19 0.01 0.00 0.00 0.04
ZM135M.PL10a C 0.25 0.78 0.12 0.32 0.01 0.12 0.09 0.08 0.00 0.22
25710-2.43 C 0.32 0.73 0.96 1.33 0.48 0.58 0.30 0.24 0.01 0.18
CNE8 AE 0.00 0.13 0.03 0.02 0.00 0.01 0.01 0.00 0.00 0.02
TRO.11 B 1.04 1.88 0.67 1.10 0.27 0.70 0.01 0.24 0.00 0.49
X1632_S2_B10 G 1.66 1.91 0.22 0.29 0.06 0.10 0.09 0.00 0.00 0.04
Ce1176_A3 C 0.00 0.28 0.21 0.44 0.00 0.16 0.02 0.15 0.01 0.14
246-F3_C10_2 AC N/A N/A 0.53 0.60 N/A N/A N/A N/A N/A N/A
CNE55 AE 0.34 0.81 0.12 0.13 0.00 0.00 0.03 0.00 0.02 0.02
Heterologous 
Strain Clade Day -7 Week 24 Day -7 Week 24 Day 0 Week 24 Day -7 Week 24 Day -7 Week24
YU2.DG B 1.10 1.64 0.04 0.11 0.16 0.06 0.14 0.15 0.00 0.14
BaL.26 B 2.10 2.81 2.16 2.75 1.11 1.45 1.18 1.71 0.00 0.26
Q769.d22 A1 0.03 0.43 0.08 0.38 0.04 0.26 0.24 0.28 0.01 0.61
Q259.d2.17 A1 N/A N/A N/A N/A 0.20 0.20 0.07 0.42 0.01 0.25
Q842.d12 A1 1.42 1.36 0.02 0.12 0.09 0.23 0.19 0.59 0.00 0.46
ZM135M.PL10a C 0.11 0.55 0.13 0.86 0.16 0.24 0.09 0.23 0.09 0.31
25710-2.43 C 0.62 1.88 0.55 0.98 0.38 0.29 0.47 1.15 0.01 0.00
CNE8 AE 0.47 1.48 0.06 0.79 0.00 0.00 0.03 0.16 0.00 0.02
TRO.11 B 1.61 2.86 0.38 0.83 0.34 0.15 0.16 0.42 0.02 0.12
X1632_S2_B10 G 0.13 0.80 0.08 0.42 0.18 0.05 0.13 0.15 0.01 0.03
Ce1176_A3 C 0.24 1.53 0.00 0.04 0.12 0.00 0.04 0.07 0.08 0.00
246-F3_C10_2 AC N/A N/A N/A N/A 0.22 0.02 N/A N/A 0.18 0.00
CNE55 AE 0.04 0.07 0.02 0.00 0.00 0.01 0.04 0.00 0.02 0.08
Heterologous 
Strain Clade Day 0 Week 24 Day 0 Week 24 Day 0 Week 24 Day 0 Week 24 Day 0 Week 24
YU2.DG B 0.00 0.28 0.08 0.30 0.00 0.13 0.28 0.52 0.00 0.53
BaL.26 B 1.40 2.12 2.24 2.71 1.27 2.33 1.26 1.74 0.63 1.77
Q769.d22 A1 0.48 1.05 0.00 0.50 0.00 0.80 0.47 0.40 0.17 0.73
Q259.d2.17 A1 0.03 0.24 0.30 0.14 0.30 0.18 0.34 0.62 0.13 0.73
Q842.d12 A1 0.02 0.19 0.12 0.19 0.16 0.24 0.36 0.59 0.25 0.56
ZM135M.PL10a C 0.00 0.14 0.24 0.13 0.15 0.37 0.53 0.35 0.12 0.21
25710-2.43 C 0.60 0.65 0.47 0.46 0.42 0.61 1.02 0.99 0.07 0.22
CNE8 AE 0.05 0.07 0.03 0.15 0.04 0.02 0.93 1.32 0.05 0.10
TRO.11 B 0.65 1.14 0.40 0.18 0.34 0.38 0.99 0.80 0.14 0.30
X1632_S2_B10 G 0.16 0.26 0.22 0.41 0.01 0.32 0.21 0.30 0.04 0.51
Ce1176_A3 C 0.21 0.02 0.12 0.00 0.05 0.00 0.34 0.13 0.12 0.15
246-F3_C10_2 AC 0.18 0.51 0.39 0.14 0.17 0.14 0.83 0.57 0.19 1.13













Heterologous TZM.bl neutralization data of purified patient IgG (AUC), continued
3BNC117-treated patients on-ART
Heterologous 
Strain Clade Day 0 Week 24 Day 0 Week 24 Day 0 Week 24 Day 0 Week 24 Day 0 Week 24
YU2.DG B 0.04 0.02 0.03 0.01 0.07 0.18 0.04 0.03 0.06 0.05
BaL.26 B 0.05 0.02 0.91 0.87 1.30 2.31 0.26 0.44 0.12 0.11
Q769.d22 A1 0.01 0.46 0.01 0.20 0.01 0.07 0.03 0.18 0.21 0.20
Q259.d2.17 A1 0.20 0.21 0.09 0.27 0.33 0.41 0.23 0.20 0.09 0.20
Q842.d12 A1 0.18 0.29 0.25 0.29 0.20 0.52 0.36 0.38 0.18 0.34
ZM135M.PL10a C 0.00 0.09 0.01 0.21 0.07 0.07 0.17 0.05 0.04 0.04
25710-2.43 C 0.01 0.08 0.05 0.23 0.12 0.23 0.18 0.17 0.42 0.46
CNE8 AE 0.00 0.00 0.00 0.03 0.01 0.13 0.02 0.00 0.09 0.08
TRO.11 B 0.11 0.09 0.17 0.05 0.36 0.49 0.12 0.11 0.24 0.27
X1632_S2_B10 G 0.00 0.00 0.00 0.00 0.00 0.05 0.00 0.05 0.14 0.09
Ce1176_A3 C 0.00 0.00 0.03 0.00 0.00 0.12 0.00 0.02 0.03 0.02
246-F3_C10_2 AC 0.03 0.01 0.01 0.00 0.00 0.02 0.00 0.00 0.00 0.00
CNE55 AE 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Heterologous 
Strain Clade Day 0 Week 24 Day 0 Week 24 Day 0 Week 24 Day 0 Week 24 Day 0 Week 24
YU2.DG B 0.00 0.02 0.03 0.11 0.00 0.02 0.07 0.05 0.28 0.19
BaL.26 B 1.18 1.22 1.37 1.10 0.15 0.21 1.77 1.85 1.32 1.43
Q769.d22 A1 0.00 0.00 0.54 0.57 0.27 0.14 0.30 0.41 0.73 0.99
Q259.d2.17 A1 0.00 0.10 0.18 0.11 0.00 0.05 0.01 0.04 0.29 0.23
Q842.d12 A1 0.10 0.08 0.18 0.41 0.08 0.20 0.19 0.12 0.56 0.59
ZM135M.PL10a C 0.00 0.02 0.18 0.13 0.03 0.14 0.18 0.25 0.30 0.52
25710-2.43 C 0.14 0.20 0.29 0.21 0.06 0.08 0.18 0.20 0.48 0.44
CNE8 AE 0.02 0.00 0.05 0.04 0.00 0.80 0.04 0.84 0.26 1.08
TRO.11 B 0.00 0.01 0.13 0.12 0.00 0.37 0.06 0.21 0.26 0.87
X1632_S2_B10 G 0.00 0.00 0.10 0.19 0.00 0.36 0.04 0.41 0.07 0.80
Ce1176_A3 C 0.01 0.04 0.08 0.10 0.06 0.13 0.12 0.09 0.10 0.53
246-F3_C10_2 AC 0.03 0.11 0.12 0.15 0.07 0.24 0.16 0.25 0.14 0.80
CNE55 AE 0.00 0.00 0.07 0.25 0.16 0.26 0.14 0.26 0.14 1.08
Heterologous 
Strain Clade Day -7 Week 24 Day -7 Week 24
YU2.DG B 0.00 0.03 0.00 0.02
BaL.26 B 0.68 0.71 1.03 1.40
Q769.d22 A1 0.20 0.00 0.01 0.07
Q259.d2.17 A1 0.00 0.09 0.00 0.29
Q842.d12 A1 0.00 0.14 0.04 0.30
ZM135M.PL10a C 0.11 0.14 0.16 0.29
25710-2.43 C 0.39 0.49 0.28 0.65
CNE8 AE 0.00 0.03 0.00 0.12
TRO.11 B 0.04 0.30 0.11 0.74
X1632_S2_B10 G 0.14 0.08 0.07 0.23 > 2
Ce1176_A3 C 0.02 0.07 0.12 0.22 1-2
246-F3_C10_2 AC N/A N/A N/A N/A 0.5 - 1
CNE55 AE 0.23 0.00 0.27 0.02 0 - 0.5
5B1 5B2 5B3 5B4 5B5




Summary measures table breadth and potency Day 0 and Wk24
Untreated viremic control individuals



























Mean AUC Wk 
24
10518 Control 2 15% 3 23% 0.305 0.413
10362 Control 2 15% 2 15% 0.393 0.352
10112 Control 11 92% 12 100% 1.809 1.692
10962 Control 13 100% 13 100% 1.492 1.536
10223 Control 13 100% 13 100% 1.595 1.497
10482 Control 4 31% 4 31% 0.407 0.423
10210 Control 5 38% 5 38% 0.594 0.537
10596 Control 9 69% 7 54% 1.096 0.962
10138 Control 11 85% 11 85% 1.634 1.566
10108 Control 13 100% 13 100% 2.739 2.701
10275 Control 1 8% 3 23% 0.409 0.422
10959 Control 8 62% 8 62% 1.186 1.193
10367 Control 11 85% 9 69% 1.645 1.514
10469 Control 8 62% 8 62% 0.724 0.676
10410 Control 1 8% 2 15% 0.267 0.396
10397 Control 3 23% 7 54% 0.525 0.623
10292 Control 6 46% 3 23% 0.530 0.468
10802 Control 1 8% 1 8% 0.222 0.225
10099 Control 4 31% 3 23% 0.376 0.384
10930 Control 12 92% 12 92% 1.420 1.254
10417 Control 8 62% 8 62% 0.915 1.023
10690 Control 7 54% 9 69% 0.656 0.714
10257 Control 9 69% 9 69% 0.845 1.009
10587 Control 6 46% 5 38% 0.669 0.598
10169 Control 13 100% 13 100% 2.009 1.789
10160 Control 5 38% 7 54% 0.682 0.627
10811 Control 5 38% 8 62% 0.481 0.807
10239 Control 2 15% 2 15% 0.391 0.330
10814 Control 3 23% 3 23% 0.378 0.390
10100 Control 1 8% 2 15% 0.159 0.225
10779 Control 2 15% 1 8% 0.371 0.343
10785 Control 2 15% 2 15% 0.482 0.429
10489 Control 3 23% 4 31% 0.422 0.465
10082 Control 1 8% 1 8% 0.288 0.238
10914 Control 7 54% 2 15% 0.548 0.291
10689 Control 2 15% 1 8% 0.410 0.359
5.1 39.1% 5.1 39.1% 0.7 0.6Average :
Untreated viremic control individuals
Breadth Overall neutralizing activity (Potency and breadth)
Table S5B. 
























with AUC > 0.5 
post-therapy
Mean AUC Day 
0
Mean AUC Wk 
24
2A1 Viremic 7 58% 10 83% 1.250 1.575
2A3 Viremic 5 38% 8 62% 0.537 0.921
2A4 Viremic 1 8% 3 25% 0.196 0.345
2B1 Viremic 1 8% 2 17% 0.144 0.180
2B3 Viremic 0 0% 1 8% 0.038 0.159
2C4 Viremic 5 45% 9 82% 0.717 1.403
2C5 Viremic 2 18% 5 45% 0.321 0.662
2D1 Viremic 1 8% 1 8% 0.230 0.227
2C1 Viremic 1 8% 3 25% 0.232 0.444
2D3 Viremic 0 0% 1 8% 0.033 0.176
2E1 Viremic 3 23% 5 38% 0.292 0.513
2E2 Viremic 1 8% 1 8% 0.384 0.442
2E3 Viremic 1 8% 3 23% 0.224 0.425
2E4 Viremic 6 46% 8 62% 0.581 0.641
2E5 Viremic 1 8% 7 54% 0.147 0.537
2.3 19.1% 4.5 36.5% 0.4 0.6
5A1 on-ART 0 0% 0 0% 0.0482 0.0976
5A2 on-ART 1 8% 1 8% 0.1204 0.1665
5A3 on-ART 1 8% 2 15% 0.1897 0.3528
5A4 on-ART 0 0% 0 0% 0.1090 0.1259
5A5 on-ART 0 0% 0 0% 0.1255 0.1437
5B1 on-ART 1 8% 1 8% 0.1137 0.1382
5B2 on-ART 2 15% 2 15% 0.2535 0.2679
5B3 on-ART 0 0% 1 8% 0.0685 0.2294
5B4 on-ART 1 8% 2 15% 0.2510 0.3820
5B5 on-ART 3 23% 10 77% 0.3799 0.7352
2B2 on-ART 1 8% 1 8% 0.1501 0.1726
2C2 on-ART 1 8% 3 25% 0.1753 0.3616
1.0 8.1% 2.1 16.6% 0.2 0.3







TZM.bl neutralization data over time in subject 2A3 (IC50)
Heterologous strain Clade Day 0 Week 12 Week 16 Week 20 Week 24
YU2.DG B >500 483.2 403.7 390.1 363.4
BaL.26 B 28.4 24.2 25.5 24.3 18.9
Q769.d22 A1 >500 452.0 266.2 82.8 19.4
Q259.d2.17 A1 92.5 61.4 71.9 93.0 84.7 0 - 25 µg/ml  
Q842.d12 A1 475.0 499.7 436.0 426.8 417.8 25 -100 µg/ml  
ZM135M.PL10a C >500 >500 >500 >500 >500 100 - 400 µg/ml    
25710-2.43 C 110.8 109.7 159.8 123.1 136.0 400 - 500 µg/ml  
CNE8 AE >500 >500 >500 >500 >500 >500 µg/ml
TRO.11 B 218.6 435.4 401.5 257.5 203.0
X1632_S2_B10 G >500 >500 >500 >500 >500
Ce1176_A3 C 482.2 >500 493.4 432.9 446.7
246-F3_C10_2 AC 445.4 430.4 420.3 299.9 283.7
CNE55 AE >500 >500 >500 >500 >500
IgG IC50 titers (µg/ml)
Table S7.
Analysis of potential confounding variables
AUC change observed 





abs. CD4+ T cell 
count              
(cells/mm3)     
Day 0 
abs. CD4+ T cell 













246.F3_C10_2 1 1 1 1 1 1 1 1
CNE55 1 1 0.18 1 1 1 1 0.18
Ce1176_A3 1 1 1 1 1 1 1 1
TRO.11 1 1 0.41 1 1 1 0.23 1
Q259.d2.17 1 1 0.10 1 1 1 1 1
25710-2.43 1 1 1 1 1 1 1 0.66
Q769.d22 1 1 0.64 1 1 1 1 0.50
BaL.26 1 0.50 0.02 1 0.09 1 1 0.47
YU.2 1 1 0.52 1 1 1 0.69 1
X1632_S2_B10 1 1 0.05 1 1 1 0.92 0.17
ZM135M.PL10a 1 1 0.37 1 1 1 1 1
Q842.d12 1 1 1 1 0.56 1 1 0.0035
CNE8 0.46 1 0.58 1 1 1 1 1
variable is not predictive of AUC change
Bonferroni-corrected significance threshold: 0.0005 with significance level α 
= 0.05
 Variable (p-value of likelihood ratio test if alternative model superior to null-model)
Table S8.
Rank correlation and p-values for Spearman rank correlation of patient and 3BNC117 neutralization
Subject ID rank correlation (AUC-based) p-value (AUC-based)
rank correlation           
(IC50-based)
p-value (IC50-based)
2A1 0.46 0.1689 -0.43 0.1369
2A3 -0.33 0.2470 0.35 0.2664
2A4 -0.52 0.1926 0.41 0.0818
2B1 0.02 0.9224 -0.03 0.9611
2B3 0.14 0.5135 -0.21 0.6641
2C4 0.39 0.2250 -0.40 0.2334
2C5 -0.12 0.8815 0.05 0.7287
2D1 -0.65 0.0103 0.70 0.0163
2C1 -0.30 0.3425 0.30 0.3355
2D3* -0.84 0.0001 0.87 0.0003
2E1 -0.62 0.0160 0.66 0.0225
2E2 -0.43 0.1926 0.41 0.1659
2E3 -0.24 0.5292 0.19 0.4364
2E4 -0.48 0.0850 0.50 0.1002
2E5 -0.38 0.1013 0.48 0.1972
2B2 -0.14 0.8690 0.06 0.6641
2C2 -0.09 0.8517 0.06 0.7700
5A1 0.00 0.8922 0.04 1.0000
5A2 0.12 0.9786 -0.01 0.7029
5A3 -0.60 0.1013 0.48 0.0293
5A4 -0.19 0.4930 0.21 0.5339
5A5 -0.21 0.4561 0.23 0.4988
5B1 0.23 0.6138 -0.15 0.4505
5B2 0.01 0.8632 -0.05 0.9644
5B3 0.24 0.3103 -0.31 0.4330
5B4 0.26 0.5785 -0.17 0.3936
5B5 0.43 0.1955 -0.38 0.1377
p-value threshold (Bonferroni-corrected): 0.0019
*Significant rank correlation only detected in 2D3 (indicated in green).
Table S9.
Subject Day 0 Week 4 (6) Week 12 Week 24 Total per patient
2A1 27 26 24 40 117
2A3 23 32 29 27 111
2C4 33 19 30 19 101
2C5 48 20 22 32 122
2E1 30 31 27 37 125
2E2 20 27 25 27 99
2E3 25 17 24 21 87
2E4 41 25 26 29 121
2E5 47 3 (22*) 23 22 117
Total per TP 294 222 230 254 1000
Number of gp160 nucleotide sequences included in phylogenetic analysis
(*) due to low viral load week 6 plasma was sequenced
Table S10. 











*3BNC117 contact sites confirmed by crystal structures (25,26) are in red
153, 295, 297, 344, 397-8, 411, 413, 444, 461, 636
32, 145, 440, 464, 683
187dehi, 337, 340, 343
80, 282, 400
Sites Under Selection (≥80% different from Day 0 Consensus)
12,134-6, 138-46, 148-9, 149lmopstuv, 150-3, 155, 161, 164, 166, 168-71, 177, 
178, 182, 185-188, 189bdef, 195, 209, 240, 270, 272, 279*, 283, 287, 291, 293, 
306, 316-7, 318,  321a, 326, 333, 335, 336-7, 343, 344, 346-7, 360, 362, 364, 365, 
373, 386, 395, 398, 401-5, 408, 411-3, 417, 442, 460, 461, 471, 698
137-8, 140, 141af, 142, 187e, 336, 410
59, 188ckl, 283, 308, 339, 346-7, 354, 356, 362, 386, 389, 392-6, 400-5, 410, 415, 
459abhijkl, 640, 674, 689, 742
140, 275, 279, 290, 340, 344, 347, 350, 353, 355, 364a, 396, 397, 400-3, 405-7, 
409, 461, 461abce, 464, 465, 500
141, 147-9, 150b, 160, 398, 401-4, 410, 460, 463, 500, 624
Table S11. 
TZM.bl neutralization data of CMV-env pseudotyped viruses (IC50)
Subject 
ID
Virus ID (in order of 





Day 0 IgG 
IC50 
(µg/ml)
Week 24 IgG 
IC50    
(µg/ml)
2A1-D0-0408TIT-E5_S57 0.119 101.1 33.4
2A1_D0_0409_G3_S89 0.209 333.6 66.6
2A1-D0-0409-B1_S73 0.116 161.5 70.1
2A1-W4-0408TIT-G11_S19 0.157 233.4 109.2 3BNC117 IC50 IgG IC50
2A1-D0-0409-E7_S85 0.141 96.9 94.5 (µg/ml) (µg/ml)
2A1-W24-0409-H4_S33 0.306 185.1 199.5 0 - 0.1 0 - 50
2A1-W24-0409-E1_S22 0.641 171.3 157.6 0.1 - 0.5 50 -100
2A1-W12-TIT0402-D1_S36 0.691 154.3 160.3 0.5 - 1.0 100 - 150
2A1-W24-0409-G11_S30 0.585 175.6 187.1 1.0 - 2.0 150 - 200
2A1-D0-0409-C2_S77 0.692 149.4 135.1 2.0 - 5.0 200 - 250
2A1-W4-0408TIT-H2_S16 0.595 164.2 153.9 5.0 - 10.0 250 - 500
2A1-D0-0409-G9_S90 0.651 165.8 154.5 > 10.0 > 500
2A1-W4-0408TIT-E12-S4 0.184 198.4 96.3
2A1-W4-0408TIT-G9_S12 0.181 266.1 143.2
2A1-W4-0408TIT-G10_S13 0.128 164.9 85.4
2A1-D0-0409-B4-S74 0.317 423.9 186.6
2A1-W24-0409-H11_S34 0.240 176.1 113.6
2A1-W4-0408TIT-F8_S6 0.159 239.1 127.1
2A1-D0-0409-H9_S93 0.008 123.4 139.4
2A1-D0-0409-E5_S83 0.017 187.2 180.6
2E1-D0-0409-E4_S58 0.038 107.7 77.3
2E1-W4_G11_S39 0.185 257.7 23.8
2E1-W4-TIT0408-D3_S63 0.048 338.1 29.1
2E1-D0-0409-H8_S69 0.124 211.0 73.6
2E1-W4-TIT0408-D7_S64 0.106 384.6 38.0
2E1-W12-0409-H3_S20 0.025 >500.0 233.5
2E1-W12-0409-G3_S16 0.063 >500.0 >500.0
2E1-W24-0526PlE-A9_S72 0.052 333.9 154.8
2E1-W24-0526PlE-B3_S74 0.080 >500.0 452.1
2E1-D0-0421-G4_S4 0.091 421.4 97.6
2E1-W4-TIT0408-E7_S69 0.078 360.5 33.5
2E1-W12-0524Pl2-F6_S49 0.087 >500.0 94.6
2E1-W24-0526PlE-G6_S85 0.064 266.7 189.6
2E1-W24-0526PlE-F1e_S80 0.040 370.5 197.9
2C5-W24-0423-H6_S78 >20 22.5 30.2
2C5-D0-0422-H4-S56 0.006 36.4 35.9
2C5-D0-0422-F4-S44 0.011 20.3 34.5
2C5-W24-0423-F2-S73 0.022 145.7 500.0
2C5-W4-0423-A6-S33 3.131 18.1 20.6
2C5-W4-0423-D11_S38 14.079 49.9 12.2
2C5-W12-TIT0418-D2_S6 1.142 2.5 2.8
2C5-W4-0422-G1_S91 >20 85.1 38.1
2A3-W24-TIT0406-B6_S68 0.195 >500.0 407.2
2A3_D0_0404_C9_S75 0.055 543.9 210.4
2A3-D0-0421-A3_S44 0.171 >500.0 >500.0
2A3-W4-0421-E11_S55 1.024 255.2 218.5
2A3-W24-TIT0406-B7_S69 0.022 411.3 419.5
2A3-W24-TIT0406-A6e_S65 0.071 292.9 327.8
2A3-W12-0421-A7_S84 0.051 255.2 182.0
2A3-D0-0421-D3_S50 0.037 305.6 212.7
2A3-W24-TIT0406-C11_S74 0.049 224.0 223.0
2A3-W12-0421-C12_S94 0.055 293.6 263.7
2A3-W12-0406-F2_S50 0.049 276.5 168.6
2A3-W4-0406-E12_S31 0.030 169.3 11.1
2A3_D0_0404_C1_S74 0.074 447.4 155.9
2A3-W4-0406-A3_S14 0.099 >500.0 219.3
2C4-W24-0406-A5_S65 >20 240.8 36.1
2C4-W24-0406-H10_S88 >20 156.7 39.2
2C4-W24-0406-D6_S74 >20 153.9 39.0
2C4-D0-0404-C1_S30 >20 195.7 21.9
2C4-D0-0406-H7_S24 >20 155.3 20.7
2C4-D0-0406-F3_S19 >20 147.6 20.4
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